Biomarkers of Alzheimer's Disease and Cerebrovascular Disease in Relation to Depressive Symptomatology in Individuals With Subjective Cognitive Decline.

"Conflict of Interest H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work); K.B. has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper; S.K. has served at scientific advisory boards and/ or as consultant for Geras Solutions and Biogen; M.Z.F., P.D.-G., N.C., T.R.S., L.R., S.S., M.W., A.Z., V.H., A.S., E.W., I.S., and D.F. declare no conflict of interest."

"Funding This work was supported by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALF965812, ALF 716681, ALFGBG-715986, FoUI-962240), the Swedish Foundation for Strategic Research (SSF), the Swedish Research Council (2012-5041, 2013-8717, 2015-02830, 2016-01590, 2017-00639, 2019-01096, 2022-00916), Swedish Research Council for Health, Working Life and Welfare (2013-1202, 2018-00471, AGECAP 2013-2300, 2013-2496, 2018-00471), Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Hjärnfonden (FO2014-0207, FO2016-0214, FO2018-0214, FO2019-0163, FO2020-0235), Alzheimerfonden (AF-554461, AF-647651, AF-743701, AF-844671, AF-930868, AF-940139, AF-968441), Eivind och Elsa K:son Sylvans stiftelse, Center for Innovative Medicine (CIMED), Gamla Tjänarinnor, Gun och Bertil Stohnes Stiftelse, Demensfonden, Karolinska Institutet Forskningsstiftelser, Funding at Karolinska Institute for Geriatric Diseases. M.Z.F was financed by a grant from the Spanish Science, Innovation and Universities Ministry (FPU17/03428). H.Z. is a Wallenberg Scholar supported by grants from the Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). M.W. was financed by a grant from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-965525). S.K. was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-965923, ALFGBG-81392, ALF GBG-771071), the Alzheimerfonden (AF-842471, AF-737641, AF-939825). The Swedish Research Council (2019-02075), Psykiatriska Forskningsfonden, Stiftelsen Demensfonden, Stiftelsen Hjalmar Svenssons Forskningsfond, Stiftelsen Wilhelm och Martina Lundgrens vetenskapsfond. K.B. is supported by the ADDF, USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the National Institute of Health, USA, (grant #1R01AG068398-01), and the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495)."